RhumbLine Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $197M | Sell |
396,380
-26,760
| -6% | -$11.9M | 0.15% | 99 |
|
|
2026
Q1 | $189M | Sell |
423,140
-8,122
| -2% | -$3.79M | 0.16% | 100 |
|
|
2025
Q4 | $196M | Sell |
431,262
-16,666
| -4% | -$7.18M | 0.16% | 102 |
|
|
2025
Q3 | $175M | Sell |
447,928
-6,444
| -1% | -$2.69M | 0.14% | 115 |
|
|
2025
Q2 | $202M | Buy |
454,372
+3,341
| +0.7% | +$1.54M | 0.17% | 95 |
|
|
2025
Q1 | $219M | Buy |
451,031
+8,670
| +2% | +$4.04M | 0.2% | 84 |
|
|
2024
Q4 | $178M | Sell |
442,361
-7,335
| -2% | -$3.4M | 0.16% | 99 |
|
|
2024
Q3 | $209M | Sell |
449,696
-8,209
| -2% | -$3.94M | 0.19% | 90 |
|
|
2024
Q2 | $215M | Sell |
457,905
-5,322
| -1% | -$2.31M | 0.2% | 84 |
|
|
2024
Q1 | $194M | Buy |
463,227
+4,739
| +1% | +$2M | 0.19% | 96 |
|
|
2023
Q4 | $187M | Sell |
458,488
-5,263
| -1% | -$1.94M | 0.2% | 95 |
|
|
2023
Q3 | $161M | Buy |
463,751
+425
| +0.1% | +$149K | 0.19% | 94 |
|
|
2023
Q2 | $163M | Buy |
463,326
+12,895
| +3% | +$4.34M | 0.18% | 94 |
|
|
2023
Q1 | $142M | Buy |
450,431
+23,694
| +6% | +$7.11M | 0.18% | 104 |
|
|
2022
Q4 | $123M | Buy |
426,737
+18,554
| +5% | +$5.65M | 0.17% | 113 |
|
|
2022
Q3 | $118M | Buy |
408,183
+12,188
| +3% | +$3.51M | 0.18% | 107 |
|
|
2022
Q2 | $112M | Buy |
395,995
+16,679
| +4% | +$4.46M | 0.16% | 112 |
|
|
2022
Q1 | $99M | Sell |
379,316
-12,950
| -3% | -$3.07M | 0.13% | 142 |
|
|
2021
Q4 | $86.1M | Buy |
392,266
+6,992
| +2% | +$1.36M | 0.11% | 163 |
|
|
2021
Q3 | $69.9M | Sell |
385,274
-15,482
| -4% | -$3.02M | 0.09% | 182 |
|
|
2021
Q2 | $80.8M | Sell |
400,756
-105,890
| -21% | -$22.1M | 0.11% | 164 |
|
|
2021
Q1 | $109M | Sell |
506,646
-15,606
| -3% | -$3.43M | 0.15% | 123 |
|
|
2020
Q4 | $123M | Buy |
522,252
+2,345
| +0.5% | +$538K | 0.17% | 108 |
|
|
2020
Q3 | $141M | Sell |
519,907
-12,657
| -2% | -$3.49M | 0.22% | 83 |
|
|
2020
Q2 | $155M | Buy |
532,564
+28,578
| +6% | +$7.75M | 0.26% | 70 |
|
|
2020
Q1 | $120M | Buy |
503,986
+2,341
| +0.5% | +$537K | 0.25% | 73 |
|
|
2019
Q4 | $110M | Sell |
501,645
-9,394
| -2% | -$1.9M | 0.18% | 106 |
|
|
2019
Q3 | $86.6M | Buy |
511,039
+24,490
| +5% | +$4.33M | 0.16% | 125 |
|
|
2019
Q2 | $89.2M | Buy |
486,549
+5,764
| +1% | +$1.01M | 0.17% | 114 |
|
|
2019
Q1 | $88.4M | Buy |
480,785
+26,369
| +6% | +$4.87M | 0.17% | 113 |
|
|
2018
Q4 | $75.3M | Buy |
454,416
+6,412
| +1% | +$1.11M | 0.16% | 118 |
|
|
2018
Q3 | $86.3M | Sell |
448,004
-5,113
| -1% | -$910K | 0.17% | 118 |
|
|
2018
Q2 | $77M | Buy |
453,117
+12,823
| +3% | +$1.99M | 0.16% | 132 |
|
|
2018
Q1 | $71.8M | Sell |
440,294
-7,641
| -2% | -$1.25M | 0.15% | 140 |
|
|
2017
Q4 | $67.1M | Buy |
447,935
+20,478
| +5% | +$3.03M | 0.14% | 153 |
|
|
2017
Q3 | $65M | Buy |
427,457
+6,137
| +1% | +$924K | 0.14% | 146 |
|
|
2017
Q2 | $54.3M | Buy |
421,320
+2,799
| +0.7% | +$337K | 0.12% | 169 |
|
|
2017
Q1 | $45.8M | Buy |
418,521
+2,759
| +0.7% | +$243K | 0.11% | 202 |
|
|
2016
Q4 | $30.6M | Buy |
415,762
+17,833
| +4% | +$1.45M | 0.08% | 269 |
|
|
2016
Q3 | $34.7M | Buy |
397,929
+20,841
| +6% | +$1.97M | 0.1% | 219 |
|
|
2016
Q2 | $32.4M | Buy |
377,088
+16,406
| +5% | +$1.42M | 0.1% | 221 |
|
|
2016
Q1 | $28.7M | Buy |
360,682
+13,790
| +4% | +$1.25M | 0.09% | 231 |
|
|
2015
Q4 | $43.6M | Sell |
346,892
-1,083
| -0.3% | -$131K | 0.14% | 141 |
|
|
2015
Q3 | $36.2M | Buy |
347,975
+4,261
| +1% | +$547K | 0.12% | 167 |
|
|
2015
Q2 | $42.4M | Sell |
343,714
-105
| -0% | -$13.2K | 0.14% | 153 |
|
|
2015
Q1 | $40.6M | Buy |
343,819
+3,623
| +1% | +$434K | 0.12% | 174 |
|
|
2014
Q4 | $40.4M | Sell |
340,196
-6,337
| -2% | -$714K | 0.12% | 178 |
|
|
2014
Q3 | $38.9M | Sell |
346,533
-15,156
| -4% | -$1.44M | 0.12% | 183 |
|
|
2014
Q2 | $34.2M | Buy |
361,689
+4,678
| +1% | +$328K | 0.1% | 192 |
|
|
2014
Q1 | $25.2M | Buy |
357,011
+6,245
| +2% | +$495K | 0.07% | 248 |
|
|
2013
Q4 | $26.1M | Buy |
350,766
+68,474
| +24% | +$4.77M | 0.08% | 239 |
|
|
2013
Q3 | $21.4M | Sell |
282,292
-104,222
| -27% | -$8.29M | 0.07% | 290 |
|
|
2013
Q2 | $30.9M | Buy |
+386,514
| New | +$28.5M | 0.1% | 196 |
|
Other funds holding VRTX
RhumbLine Advisers's VRTX Position: Q2 2026 in Review
RhumbLine Advisers reduced its Vertex Pharmaceuticals (VRTX) stake by 6.3% in Q2 2026, selling an estimated $11.9M and leaving 396,380 shares worth $197M. The position accounts for 0.15% of the portfolio, ranked #99.
RhumbLine Advisers first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $219M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- RhumbLine Advisers held 396,380 shares of Vertex Pharmaceuticals worth $197M as of Q2 2026.
- RhumbLine Advisers sold 26,760 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.9M.
- Vertex Pharmaceuticals made up 0.15% of RhumbLine Advisers's portfolio in Q2 2026, its #99 holding.
- RhumbLine Advisers first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Vertex Pharmaceuticals position peaked at $219M in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.